Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial.
- DOI
- 10.1016/s2213-8587(24)00313-9
- Published
- 2025 Mar
- Container
- The lancet. Diabetes & endocrinology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/s2213-8587-24-00313-9,
title = {Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial.},
author = {Raal FJ and Mehta V and Kayikcioglu M and Blom D and Gupta P and Elis A and Turner T and Daniels C and Vest J and Mitchell T and Caldwell K and Bahassi EM and Kallend D and Stein EA},
year = {2025},
journal = {The lancet. Diabetes \& endocrinology},
doi = {10.1016/s2213-8587(24)00313-9},
url = {https://doi.org/10.1016/s2213-8587(24)00313-9}
}RIS
TY - JOUR TI - Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial. AU - Raal FJ AU - Mehta V AU - Kayikcioglu M AU - Blom D AU - Gupta P AU - Elis A AU - Turner T AU - Daniels C AU - Vest J AU - Mitchell T AU - Caldwell K AU - Bahassi EM AU - Kallend D AU - Stein EA PY - 2025 JO - The lancet. Diabetes & endocrinology DO - 10.1016/s2213-8587(24)00313-9 UR - https://doi.org/10.1016/s2213-8587(24)00313-9 ER -
APA
FJ, R., V, M., M, K., D, B., P, G., A, E., T, T., C, D., J, V., T, M., K, C., EM, B., D, K., & EA, S. (2025). Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial.. The lancet. Diabetes & endocrinology. https://doi.org/10.1016/s2213-8587(24)00313-9
Source records
- pubmed · retrieved 2026-09-26T03:04:56.912Z